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Abstract
Background: Although gender differences have been observed in the severity of axial spondyloarthritis (axSpA),
gender differences in disease presentation of early axSpA have not been thoroughly investigated. In particular,
their impact on the diagnostic process is unknown.
Methods: Baseline data from the SPondyloArthritis Caught Early cohort, which includes patients with chronic
back pain (CBP; duration ≥ 3 months and ≤ 2 years, age of onset < 45 years), were analysed. Patients underwent a
full diagnostic work-up, including MRI and radiograph of the sacroiliac joints (MRI-SIJ and X-SIJ), to establish a
diagnosis of axSpA. Characteristics of male and female patients with a certain diagnosis of axSpA (confidence
level by the physician ≥ 7 on a 0–10 rating scale) were compared. Regression models were built for: the whole
CBP cohort stratified by gender, to study which SpA features were associated most with diagnosis in each
gender; and for axSpA patients, to test whether gender was associated with imaging positivity (MRI-SIJ+ and/or X-
SIJ+).
Results: Of the 719 CBP patients, 275 were male. With 146/275 males and 155/444 females diagnosed as axSpA,
males were more likely to be diagnosed with axSpA (OR 2.1, 95% CI 1.5–2.9). Despite similar symptom duration,
male axSpA patients were younger at diagnosis (27.4 ± 7.5 vs 29.5 ± 7.8 years; p = 0.02). Presence of SpA features
was similar in male and female axSpA patients, except for HLA-B27 and imaging positivity that were more
common in male axSpA patients (80% vs 60%; p < 0.01 and 78% vs 64%; p = 0.01). Nevertheless, these SpA
features were still more prevalent in female axSpA patients than in no-axSpA patients, both females (HLA-B27+
23%, positive imaging 7%) and males (HLAB27+ 34%, positive imaging 11%) (all p < 0.01). Moreover, in multivariable
models with diagnosis of axSpA as outcome, HLA-B27 and imaging positivity were associated with the diagnosis in
both sexes. In models with imaging positivity as outcome, male gender and HLA-B27 were both independently
associated with MRI+ and/or X-SI+.
Conclusions: While our data show clear gender differences in early axSpA, they highlight that HLA-B27 and imaging
are still key elements for diagnosis in both genders. Our study does not suggest that separate diagnostic strategies for
men and women are required.
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Background
Spondyloarthritis (SpA) refers to a group of chronic in-
flammatory diseases that, according to the Assessment of
SpondyloArthritis international Society (ASAS) classifica-
tion criteria, may be divided by the predominant site of
involvement into axial SpA (axSpA) and peripheral SpA
[1, 2]. In addition, axSpA can be further split into radio-
graphic axSpA (r-axSpA, also known as ankylosing spon-
dylitis), characterised by typical radiographic changes in
sacroiliac joints (SIJ) [3], and non-radiographic axSpA, a
form of the disease in which structural damage in the SIJ
is not (yet) present.
Although axSpA affects both men and women,
r-axSpA is more common in males, with a reported male
to female ratio of 2–3:1 [4–6]. The higher incidence of
r-axSpA in males compared to females has stimulated
research on gender differences in this disease. In patients
with longstanding r-axSpA, males have more severe
radiographic damage and often more inflammation [7–
11]. On the other hand, some authors have reported that
female r-axSpA patients more often have cervical spine
involvement, peripheral pain, and worse patient-reported
outcomes (PROs) [7, 10, 12, 13]. Moreover, a longer time
frame between symptom onset (based on patient history)
and diagnosis has been repeatedly noticed in female
r-axSpA patients [9, 14]. This finding poses the question
of whether there is an earlier presentation of the disease
in males or an earlier detection of the disease after its
onset. If there were phenotypical gender differences at
the start or diagnosis of the disease, with less typical
findings in women, this could result in a delayed diagno-
sis. The importance of gender differences in the entire
axSpA spectrum has only recently been appreciated, es-
pecially since an earlier diagnosis of axSpA has become
more feasible. Few studies have been performed in co-
horts with early disease such as the German Spondyloar-
thritis Inception Cohort (GESPIC) and the DEvenir des
Spondylarthropathies Indifférenciées Récentes (DESIR)
cohort [15, 16], with only one report specifically focusing
on possible gender differences [16]. In the GESPIC co-
hort, composed of patients with a certain diagnosis of
axSpA and a mean disease duration approaching 4 years,
male gender was independently associated with more
radiographic damage [15]. In the DESIR cohort, which
includes patients with a high likelihood of SpA (inflam-
matory back pain highly suspected of axSpA), in the
subgroup of patients who fulfilled the ASAS criteria,
males were younger at diagnosis, had higher C-reactive
protein (CRP) levels, and more often had radiographic
sacroiliitis and/or signs of inflammation of SIJ and the
spine on magnetic resonance imaging (MRI) [16]. Both
studies include only patients with an established (or at
least very likely) diagnosis and do not have subjects
without axSpA for comparison.
Given the clear gender difference in established
r-axSpA, it would be important to know whether differ-
ences between male and female axSpA patients are already
present early in the disease. If so, different diagnostic strat-
egies may be needed for males and females, considering
that diagnostic delay is reported to be higher in females
[17, 18]. Therefore, we set out to analyse gender differ-
ences at the moment of diagnosis of axSpA in a large in-
ception cohort of chronic back pain (CBP) patients of
unknown origin. Our aim was to assess differences in dis-
ease presentation between males and females in early
axSpA, and to determine whether different SpA features
are important for the diagnosis of axSpA in the two gen-
ders, possibly demanding separate diagnostic strategies.
Methods
Study design and population
The SPondyloArthritis Caught Early (SPACE) cohort is
an ongoing prospective multicentre study which was ini-
tiated in January 2009 and has been described in detail
elsewhere [19]. In brief, patients with CBP (≥ 3 months
and ≤ 2 years of duration) of unknown origin and age of
onset < 45 years are included. Patients have been re-
cruited from six different rheumatology outpatient
clinics in the Netherlands (Amsterdam, Gouda, Leiden),
Norway (Oslo), Sweden (multiple sites), and Italy
(Padua). For the present analysis, baseline data were
available for 740 patients (SPACE database lock, March
2017). Patients with missing information on clinical
diagnosis or imaging were excluded (n = 21), resulting in
719 patients who could be included in the current
analyses.
Patients enrolled in the cohort underwent a full diagnos-
tic work-up, including the assessment of SpA features ac-
cording to the definitions of the ASAS criteria [2].
Consequently, the actual presence or history of the follow-
ing SpA features was ascertained: inflammatory back pain
(IBP), good response to non-steroidal anti-inflammatory
drugs (NSAIDs), positive family history of SpA (family his-
tory in first or second-degree relatives of r-axSpA, uveitis,
reactive arthritis, inflammatory bowel disease, or psoriasis),
peripheral arthritis, dactylitis, enthesitis, acute anterior uve-
itis, inflammatory bowel disease, and psoriasis. Additional
details from the patient history were recorded, including
their smoking history which was treated as a categorical
variable (yes/no/past smoker). The clinical examination in-
cluded tender/swollen joint and the Maastricht Ankylosing
Spondylitis Enthesitis Score (MASES) [20].
In addition to the clinical SpA features, CRP, the
erythrocyte sedimentation rate (ESR), and human
leukocyte antigen (HLA)-B27 were measured, and plain
radiographs of the pelvis (X-SIJ) in the anteroposterior
view and MRI-SIJ were performed. Each centre inter-
preted X-SIJ and MRI-SIJ with respect to the presence
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or absence of sacroiliitis using global assessment as part
of routine clinical practice (local reading), with radiolo-
gists and rheumatologists whom had specifically been
asked whether there was evidence of sacroiliitis.
Moreover, radiographs of the spine (X-spine) in the sa-
gittal view were taken and centrally scored by three
well-trained readers. A syndesmophyte was considered
present if detected at the same vertebral corner by at
least two readers.
Based on the collected local information, rheumatolo-
gists provided a diagnosis of ‘axSpA’ or ‘no axSpA’. In
addition, they were requested to provide a level of confi-
dence for their diagnosis on an 11-point numerical rat-
ing scale ranging from 0 (not confident at all) to 10
(very confident).
In this study, we considered as ‘axSpA patients’ those
who received a diagnosis of axSpA by the rheumatolo-
gist with a level of confidence ≥ 7. This subgroup is
hereafter simply referred to as axSpA. ‘No-axSpA pa-
tients’ included patients with a diagnosis of ‘no axSpA’
and patients with an uncertain diagnosis of axSpA (level
of confidence < 7).
Statistical analysis
Patient and disease characteristics were compared be-
tween male and female patients, in both groups of
axSpA and no-axSpA patients, using the Mann–Whitney
U test or t test for continuous variables and the
chi-square or Fisher exact test, as appropriate. Results
are presented as frequency (%) or mean (standard devi-
ation (SD)). In order to evaluate which SpA features
contributed most to the clinical diagnosis of axSpA,
multivariable logistic regression models were built using
the whole SPACE cohort stratified by gender. SpA fea-
tures were used as the independent variables of interest,
and a certain diagnosis of axSpA as the outcome. The
SpA features were forced into the multivariable regres-
sion models, regardless of their significance in univari-
able analyses.
Furthermore, in axSpA patients, the relationship be-
tween gender and imaging abnormalities was investi-
gated through logistic models with X-SIJ+, MRI-SIJ+ or
any positive imaging (X-SIJ+ and/or MRI-SIJ+) as the
outcomes. Independent variables, apart from gender,
consisted of possible determinants of the outcome or
potential confounders based on previous studies [21,
22], namely positive family history of SpA, elevated CRP
or ESR, and variables that had shown a statistically sig-
nificant difference between male and female axSpA pa-
tients in our baseline data. The independent variables
showing an association with the outcome in univariable
analyses with p < 0.10 were subsequently included in the
multivariable model.
Results of regression analyses were expressed in terms
of odds ratio (OR) and 95% confidence interval (95% CI).
Data analysis was performed using STATA SE version
14 (StataCorp, College Station, TX, USA) and p ≤ 0.05
was considered significant.
Results
A total of 719 patients with CBP were analysed. Their
mean age was 29.0 (SD 8.2) years, and the mean CBP
duration was 13.2 (6.9) months. The majority of patients
(n = 444, 62%) were females, with a male to female ratio
of 1:1.6. The clinical, laboratory, and imaging character-
istics of the CBP population are presented in Table 1.
Out of the 719 CBP patients, 301 patients (42%) were
diagnosed with axSpA by the rheumatologist with a level
of confidence (LoC) ≥ 7 (axSpA patients). An additional
82 patients (35% males) out of 719 received a diagnosis
of axSpA with a level of confidence in diagnosis < 7
(here included in the no-axSpA group).
Of the 275 male CBP patients, 146 (53%) received a
certain diagnosis of axSpA, and of the 444 female CBP
patients, 155 (35%) received a certain diagnosis of
axSpA, showing that male patients with CBP were sig-
nificantly more likely to be diagnosed with axSpA (OR
Table 1 Baseline characteristics and SpA features of chronic
back pain patients included in the SPACE cohort (n = 719)
Characteristic Value
Male gender, n (%) 275 (38)
Age at CBP onset (years), mean (SD) 29.0 (8.0)
Duration of CBP (months), mean (SD) 13.2 (6.9)
Alternating buttock pain, n (%) (N = 454a) 225 (55)
IBP, n (%) 499 (70)
Response to NSAIDs, n (%) 316 (45)
Family history of SpA, n (%) 305 (43)
Peripheral arthritis, n (%) 111 (15)
Heel enthesitis, n (%) 142 (20)
Dactylitis, n (%) 39 (5)
Uveitis, n (%) 58 (8)
Psoriasis, n (%) 88 (12)
IBD, n (%) 48 (6)
HLA-B27+, n (%) 315 (44)
Elevated CRP/ESR, n (%) 217 (30)
MRI-SIJ+, n (%) 234 (32)
X-SIJ+, n (%) 91 (12)
Any positive imaging,b n (%) 250 (34)
SpA spondyloarthritis, SPACE SPondyloArthritis Caught Early, CBP chronic back
pain, IBP inflammatory back pain, NSAID non-steroidal anti-inflammatory drug,
IBD inflammatory bowel disease, HLA human leukocyte antigen, CRP C-reactive
protein, ESR erythrocyte sedimentation rate, MRI-SIJ magnetic resonance imaging
of sacroiliac joints, X-SIJ plain radiograph of sacroiliac joints
aMissing data < 5% unless otherwise indicated
bMRI-SIJ+ and/or X-SIJ+
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2.1, 95% CI 1.5–2.9). When the patients with a low
certainty diagnosis of axSpA (LoC < 7) were removed
from the no-SpA group and added to the axSpA
group, the gender difference remained the same (OR
2.0, 95% CI 1.5–2.7).
In the axSpA group, the mean age was 28.5 (7.8) years
and the mean CBP duration was 13.3 (7.0) months. The
male to female ratio was 1:1.1, with 146 (48%) males and
155 (52%) females. Male axSpA patients were younger
than female axSpA patients at the time of diagnosis
(27.4 (7.5) years vs 29.5 (7.8) years, p = 0.02; Table 2).
Among axSpA patients, most SpA features were simi-
larly distributed between the two genders. However,
males were significantly more often HLA-B27+ (80% vs
60%; p < 0.001) and more often had imaging abnormal-
ities (any positive imaging 78% vs 64%; p = 0.007) than
axSpA female patients. The latter was mainly due to the
fact that more males than females had both a positive
MRI-SI and a positive X-SI (30% vs 17%; p = 0.006).
Moreover, although syndesmophytes were uncommon in
these patients with early disease, more males than fe-
males had syndesmophytes present (8% vs 1%; p = 0.02).
In contrast, psoriasis appeared to be more common in
females (24% vs 15%), although this difference was not
statistically significant (p = 0.051). Interestingly, the total
number of SpA features without HLA-B27 and imaging
was not different between males and females (3.5 (1.7)
vs 3.5(1.6); p = 0.99). Females were less frequently
smokers than males (10% vs 22%; p = 0.02).
In both genders, all SpA features were significantly
more common in axSpA patients as compared to
no-axSpA patients except for IBD and family history.
The latter was actually more common in male axSpA
patients compared to male no-axSpA patients, but such
a difference was not observed in female patients. Inter-
estingly, HLA-B27 and positive imaging were still more
prevalent in female axSpA patients than in no-axSpA
patients, both females (HLA-B27+ 23% and positive
Table 2 Characteristics of patients without (n = 418) and with (n = 301) certain diagnosis of axSpA stratified by gender









Age at CBP onset (years), mean (SD) 29.3 (8.6) 29.4 (8.2) 0.9 27.4 (7.5) 29.5 (7.8) 0.02
Duration of CBP (months), mean (SD) 12.8 (6.9) 13.4 (7.0) 0.5 13.3 (7.1) 13.4 (7.0) 0.5
Alternating buttock pain, n (%) (N = 454a) 23 (43) 100 (59) 0.03 65 (60) 64 (51) 0.2
IBP, n (%) 83 (57) 164 (64) 0.2 123 (84) 129 (84) 1.0
Response to NSAIDs, n (%) 45 (37) 81 (29) 0.1 92 (64) 98 (66) 0.8
Family history of SpA, n (%) 44 (34) 124 (44) 0.1 68 (46) 69 (45) 0.8
Peripheral arthritis, n (%) 15 (12) 25 (9) 0.3 37 (25) 34 (22) 0.5
Heel enthesitis, n (%) 17 (13) 28 (10) 0.3 46 (31) 51 (33) 0.7
Dactylitis, n (%) 3 (2) 4 (1) 0.5 16 (11) 16 (10) 0.9
Uveitis, n (%) 7 (5) 12 (4) 0.6 19 (13) 20 (13) 1.0
Psoriasis, n (%) 6 (5) 23 (8) 0.2 22 (15) 37 (24) 0.051
IBD, n (%) 11 (8) 15 (5) 0.2 10 (7) 12 (8) 0.8
HLA-B27+, n (%) 43 (34) 66 (23) 0.02 114 (80) 92 (60) < 0.001
Elevated CRP/ESR, n (%) 21 (16) 61 (21) 0.2 71 (49) 64 (42) 0.2
SpA features without imaging or HLA-B27, mean (SD) 2.4 (0.1) 2.1 (0.1) 0.3 3.5 (1.7) 3.5 (1.6) 1.0
MRI-SIJ+/X-SIJ–, n (%) 7 (5) 19 (6) 0.6 65 (44) 68 (44) 0.9
MRI-SIJ−/X-SIJ+, n (%) 2 (1) 4 (1) 0.9 5 (3) 5 (3) 0.9
MRI-SIJ+/X-SIJ+, n (%) 5 (4) 0 (0) 0.01 44 (30) 26 (17) 0.006
Any positive imaging,b n (%) 14 (10) 23 (7) 0.3 114 (78) 99 (64) 0.007
Number of syndesmophytes, mean (SD) (N = 182a) n/a n/a – 0.1 (0.4) 0.0 (0.1) 0.5
Patients with syndesmophytes, n (%) (N = 182a) n/a n/a – 7/83 (8) 1/99 (1) 0.02
Current smokers, n (%) 33 (28) 54 (19) 0.1 31 (22) 15 (10) 0.02
Modified Stoke ankylosing spondylitis Spine Score available for 182/301 axSpA patients. Bold data indicate significant results
axSpA axial spondyloarthritis, CBP chronic back pain, IBP inflammatory back pain, NSAID non-steroidal anti-inflammatory drug, SpA spondyloarthritis, IBD inflammatory
bowel disease, HLA human leukocyte antigen, CRP C-reactive protein, ESR erythrocyte sedimentation rate, MRI-SIJ magnetic resonance imaging of sacroiliac
joints, X-SIJ plain radiograph of of sacroiliac joints
aMissing data < 5% unless otherwise indicated
bMRI-SIJ + and/or X-SIJ+
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imaging 7%) and males (HLAB27+ 34% and positive im-
aging 11%) (all p < 0.01).
The multivariable regression model in male CBP pa-
tients, with a certain diagnosis of axSpA as an outcome,
showed that HLA-B27 positivity, elevated CRP and/or
ESR, and MRI-SIJ+ were independently associated with
the diagnosis of axSpA (Table 3).
In the female CBP population, HLA-B27 positivity,
MRI-SIJ+, and X-SIJ+ were independently associated
with the diagnosis of axSpA in the multivariable
model, but also other SpA features emerged as inde-
pendent predictors of diagnosis; specifically a positive
history or current presence of inflammatory back
pain, uveitis, psoriasis, heel enthesitis, dactylitis, IBD,
and response to NSAIDs (Table 4).
In axSpA patients, the relationship between gender
and imaging abnormalities was investigated. In the
univariable regression analysis with positive imaging
(MRI-SIJ+ and/or X-SIJ+) as the outcome (Table 5), an
independent positive association (p < 0.05) was found for
male gender, lower age at CBP onset, and HLA-B27
positivity. In the multivariable model, male gender and
HLA-B27 positivity were independently and positively
associated with imaging positivity. A positive family his-
tory of SpA showed a negative association in both the
univariable analysis and the multivariable model.
Male gender was also positively associated with
MRI-SIJ+ alone (OR 1.6, 95% CI 1.0–2.8) and with
X-SIJ+ alone (OR 1.9, 95% CI 1.1–3.3) in the multivari-
able models having MRI-SIJ+ and X-SIJ+ separately as
outcomes (data not shown).
Patient-reported outcomes, metrological indices, and
disease activity indices of axSpA patients were recorded
in the cohort and are presented in Additional file 1:
Table S1. Bath Ankylosing Spondylitis Disease Activity
Index (BASDAI) scores as well as the percentage of pa-
tients presenting with BASDAI > 4 were higher in fe-
males (4.5 (2.2) vs 3.4 (1.9) and 57% vs 34%; both p <
0.001). The Bath Ankylosing Spondylitis Functional
Index (BASFI) and Short Form (SF)-36 outcomes were
not significantly different between genders. Disease
activity based on the Ankylosing Spondylitis Disease
Activity Score (ASDAS) was similar in terms of abso-
lute value, but females more frequently had a high or
very high disease activity (ASDAS ≥ 2.1, 65% vs 46%;
p = 0.004). Similarly, total MASES was similar be-
tween males and females, but the percentage of pa-
tients with current entheseal involvement (MASES >
0) was higher in females (70% vs 41%; p < 0.001).
Finally, more female than male axSpA patients (43%
vs 20%; p = 0.002) had an extreme BASDAI score
(score ≥ 7 on a 0–10 scale in at least three questions
of the BASDAI).
Table 3 Multivariable model with certain diagnosis of axSpA
(level of confidence ≥ 7/10) as an outcome and SpA features as
independent variables in male CBP population
Independent variable OR (95% CI)
(N = 262a)
p value
HLA-B27+ 3.8 (1.7–8.8) < 0.001
IBP 2.1 (0.8–5.6) 0.1
Uveitis 1.7 (0.5–6.0) 0.3
Psoriasis 2.7 (0.6–11.2) 0.2
Heel enthesitis 2.3 (0.8–6.5) 0.09
Dactylitis 0.3 (0.0–2.4) 0.3
IBD 1.8 (0.4–7.6) 0.4
Peripheral arthritis 1.9 (0.6–6.0) 0.3
Response to NSAIDs 1.5 (0.6–3.3) 0.4
Family history of SpA 1.5 (0.7–3.6) 0.3
Elevated CRP/ESR 2.5 (1.0–6.1) 0.05
MRI-SIJ+ 24.3 (9.7–60.6) < 0.001
X-SIJ+ 2.7 (0.7–9.4) 0.1
Bold data indicate significant results
axSpA axial spondyloarthritis, SpA spondyloarthritis, CBP chronic back pain,
OR odds ratio, CI confidence interval, HLA human leukocyte antigen,
IBP inflammatory back pain, IBD inflammatory bowel disease, NSAID non-
steroidal anti-inflammatory drug, CRP C-reactive protein, ESR erythrocyte
sedimentation rate, MRI-SIJ magnetic resonance imaging of sacroiliac joints, X-
SIJ plain radiograph of of sacroiliac joints
aNumber of patients with complete data on all variables
Table 4 Multivariable model with certain diagnosis of axSpA
(level of confidence ≥ 7/10) as an outcome and SpA features
as independent variables in female CBP population
Independent variable OR (95% CI)
(N = 424a)
p value
HLA-B27+ 6.7 (3.2–14.0) < 0.001
IBP 4.0 (1.7—8.9) 0.001
Uveitis 3.1 (1.0–9.2) 0.04
Psoriasis 4.6 (1.8–12.0) 0.002
Heel enthesitis 4.3 (1.9–9.7) < 0.001
Dactylitis 5.2 (1.0–26.9) 0.05
IBD 4.7 (1.5–14.8) 0.009
Peripheral arthritis 1.4 (0.5–3.7) 0.5
Response to NSAIDs 3.1 (1.6–6.0) 0.001
Family history of SpA 0.9 (0.4–1.8) 0.8
Elevated CRP/ESR 1.7 (0.8–3.5) 0.2
MRI-SIJ+ 32.6 (14.2–75.0) < 0.001
X-SIJ+ 6.9 (1.4–32.7) 0.02
Bold data indicate significant results
axSpA axial spondyloarthritis, SpA spondyloarthritis, CBP chronic back pain,
OR odds ratio, CI confidence interval, HLA human leukocyte antigen,
IBP inflammatory back pain, IBD inflammatory bowel disease, NSAID non-
steroidal anti-inflammatory drug, CRP C-reactive protein, ESR erythrocyte
sedimentation rate, MRI-SIJ magnetic resonance imaging of sacroiliac joints,
X-SIJ plain radiograph of of sacroiliac joints
aNumber of patients with complete data on all variables
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Discussion
The analysis of gender differences in this large CBP co-
hort with short duration of complaints allowed us to
conclude that, while females are the majority of patients
in the original CBP population, males were twice as
likely to be diagnosed with axSpA. At the moment of
diagnosis of axSpA, males were younger and more often
presented with HLA-B27 positivity and imaging abnor-
malities, including a higher prevalence of syndesmo-
phytes, even though symptom duration was similar to
female patients. However, the prevalence of most other
SpA features was equally distributed between genders.
Although we noticed differences in disease presenta-
tion, the results of our study suggest that similar ele-
ments are relevant for the diagnosis of male and female
axSpA patients. In fact, despite HLA-B27 positivity and
imaging abnormalities being more common in male
axSpA patients, they were significantly associated with
diagnosing axSpA in both genders. We believe this is
this first study to examine the possible relevance of dif-
ferent SpA features in making a diagnosis stratified for
gender. This is the first report showing in a CBP cohort
that males have a higher probability to be diagnosed
with axSpA. Since all patients, suspected of axSpA or
not, in our cohort underwent the same protocol (includ-
ing extensive imaging), the gender difference cannot be
attributed to differences in the diagnostic process.
Nevertheless, it is obvious that early axSpA does not
have such a clear male gender skewing as r-axSpA, since
female patients still represent nearly half of the axSpA
population, as previously noted [15, 16]. This suggests
that specific gender disparities (e.g. radiographic evi-
dence of sacroiliitis) may become more apparent later in
the disease course.
Our finding of male patients being younger at disease
onset is in line with findings in the DESIR cohort [16];
considering the strict age span allowed by the inclusion
criteria and given that males and females in our cohort
had similarly short symptom duration, this likely reflects
a true difference in the disease onset, rather than a bet-
ter recognition of the disease in males. Previous reports
on age of onset in male and female axSpA patients
mainly concern longstanding disease, and some of them
reported that males seemed to have an earlier onset [12,
23, 24]. The mechanism behind this is unclear and de-
serves further investigation.
The results of this study also confirm that imaging ab-
normalities are more frequently found in male axSpA
patients, already at the beginning of the disease [15, 16,
24]. Moreover, we show that male sex is independently
associated with positive imaging, both in terms of MRI
inflammation and radiographic sacroiliitis. Remarkably,
syndesmophytes were more common in males at base-
line, showing that differences in radiographic damage
between genders, which have been repeatedly observed
in r-axSpA [7, 10, 11], can already be found in very early
disease. Also, radiographic or MRI sacroiliitis was the
most important item for diagnosis in women, and was
significantly more common in both male and female
axSpA patients compared to no-axSpA patients.
HLA-B27 was also more common in male axSpA
patients, and the overall prevalence of HLA-B27 in axSpA
patients in our study was similar to other early axSpA co-
horts [25]. However, it has to be noted that in other axSpA
populations, such as those of the clinical trials, where
axSpA patients are included only if they fulfil ASAS criteria
and not based solely on the rheumatologist diagnosis, often
display higher percentages of HLA-B27+ patients [26, 27].
Table 5 Factors associated with positive imaging (MRI-SIJ+ and/or X-SIJ+) in patients with certain diagnosis of axial spondyloarthritis
(level of confidence ≥ 7/10)




OR (95% CI) p OR (95% CI) p
Male gender 2.0 (1.2, 3.3) 0.007 1.8 (1.0, 3.1) 0.05
Age at CBP onset 1.0 (0.9, 1.0) 0.04 1.0 (0.9, 1.0) 0.052
HLA-B27+ 2.0 (1.2, 3.4) 0.01 1.8 (1.0, 3.3) 0.04
Positive family history of SpAb 0.4 (0.3, 0.7) 0.002 0.4 (0.2, 0.7) 0.001
Elevated CRP/ESR 1.6 (1.0, 2.7) 0.06 1.5 (0.9, 2.7) 0.1
Smoking (N=284c) 1.1 (0.8, 1.6) 0.4 NI -
Data presented as odds ratio (95% confidence interval). Bold data indicate significant results
MRI-SIJ magnetic resonance imaging of sacroiliac joints, X-SIJ plain radiograph of of sacroiliac joints, CBP chronic back pain, HLA human leukocyte
antigen, SpA spondyloarthritis, CRP C-reactive protein, ESR erythrocyte sedimentation rate, NI not included in multivariable model because p > 0.1 at univariate
analysis and no confounder
aNumber of patients with complete data on all variables
bFamily history of spondyloarthritis according to the Assessment of SpondyloArthritis international Society includes family history in first or second-degree
relatives of ankylosing spondylitis, uveitis, reactive arthritis, inflammatory bowel disease, or psoriasis
cSmoking data unavailable in five additional patients
Ortolan et al. Arthritis Research & Therapy  (2018) 20:218 Page 6 of 8
In studying the factors associated with sacroiliitis in pa-
tients with axSpA, a positive family history was protective
of positive imaging even in univariate analysis. At present
we have no clear explanation for this observation. Little is
known about differences in axial spondyloarthritis between
patients with and without a familial history. One study re-
ported that familial ankylosing spondylitis was significantly
milder than sporadic disease [28], while another found no
difference in disease phenotype [29].
Although PROs were not the main outcome of our
study, it is interesting to observe how, in line with data
from the literature, female patients in our cohorts pre-
sented with a higher subjective disease burden [7, 10, 12,
13]. Unfortunately, our cohort lacks assessment of fibro-
myalgia, but the observation of female axSpA patients pre-
senting with more extreme PROs than males suggests that
fibromyalgia could have been a frequent co-morbidity for
our axSpA patients, possibly influencing the degree of
symptom complaint in females. Indeed, it has been de-
scribed that about a third of axSpA patients could have a
neuropathic pain component [30].
A clear limitation in our analysis is that our diagnostic
models for axSpA do not truly reflect a normal diagnostic
work-up in clinical practice, in which looking for—and ex-
cluding—other causes of CBP is pivotal. However, the val-
idity of our observations derives from the fact that all of
the information included in the model was available to the
rheumatologist and was used at the moment of making
the diagnosis (axSpA/no axSpA). On the other hand,
rheumatologists certainly performed a diagnosis according
to their background knowledge and beliefs, and therefore
there could have been a tendency towards a specific inter-
pretation of the results (e.g. women could have been
under-diagnosed if the rheumatologists interpreted axSpA
as a predominantly male disease). Finally, we cannot ex-
clude that possible referral bias may have interfered with
the proportion of males and females in the study popula-
tion or with other results such as the nearly significant
prevalence of psoriasis in females. Indeed, the reasons
why GPs or medical specialists referred CBP patients to
the rheumatologists is unknown, but they could have been
more prone to refer a female CBP patient if SpA features
(besides HLA-B27 and imaging) were already present or
because they had worse symptoms, thus a channelling
mechanism cannot be excluded. However, other cohorts
have reported a higher frequency of CBP in females [31];
moreover, the male to female ratio in our axSpA popula-
tion is in line with previous findings [15, 16].
Conclusions
In summary, in patients with CBP of unknown origin,
males are more likely to be diagnosed with axSpA. In
addition, significant differences between genders, includ-
ing age at onset and imaging abnormalities, already exist
at a very early disease stage. Nevertheless, HLA-B27 and
imaging are still key elements for a diagnosis of axSpA
in both genders, and therefore our data do not support
the need for gender-specific diagnostic strategies for
early axSpA patients.
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